mostechfreespins| Financial report express: Xuerong Biotech's full-year net loss of 188 million yuan in 2023

April 26thMostechfreespinsXuerong Biology (300511) (300511), an A-share listed company, released its annual report for 2023. Of which, the net loss is 1.MostechfreespinsThe loss was 0.88 billion yuan, a year-on-year reduction of 34.52%.

According to the comprehensive operation and follow-up analysis of more than 1200 financial indicators of its financial data in the current period and the past five years, according to the financial diagnosis model of flush (300033), the overall financial situation of Xuerong biology in the past five years is lower than the industry average. Specifically, the operating capacity and asset quality are excellent.

The net loss was 188 million yuan, which was 34.52% lower than the same period last year.

In terms of revenue and profit, the company achieved a total operating income of 2.565 billion yuan during the reporting period, an increase of 10.55% over the same period last year, a net loss of 188 million yuan, a loss of 34.52% over the same period last year, and basic earnings per share of-0.38 yuan.

In terms of assets, during the company's reporting period, the total assets at the end of the period were 4.602 billion yuan and accounts receivable were 33.4804 million yuan; in terms of cash flow, the net cash flow generated by business activities was 358 million yuan, and the cash received by selling goods and providing services was 2.546 billion yuan.

There are two financial highlights.

According to the relevant financial information published by Xuerong Biology, there are two financial highlights in the company, as follows:

The average turnover rate of accounts receivable is 63.27 (times / year), and the company collects accounts quickly. Inventory turnover the average inventory turnover rate is 4.77 (times / year), and the inventory liquidity is very strong.

The financial situation is poor, there are 9 financial risks

According to the relevant financial information published by Xuerong Biology, there are nine financial risks in the company, as follows:

The average rate of return on net assets is-10.98%, and the company's profitability is poor. The average operating profit margin is-9.49%, and the company's ability to make money is poor. The average year-on-year growth rate of performance deduction non-net profit is-74.75%, and the company's growth ability is very weak. The average year-on-year growth rate of net profit is-80.82%, and the growth of the company is very low. The proportion of interest-paying debt is 56.29%, and there is a lot of pressure on debt repayment. The liquidity ratio is 0.66, and the short-term solvency is very weak. Revenue in the growth period decreased by 28.30% compared with the same period last year, with a higher decline in revenue. In the growth period, the deduction of non-net profit decreased by 101.61% compared with the same period last year, and the profit dropped greatly. Deposit and loan double high currency fund is 648 million, short-term loan is 879 million, there is high risk of both deposit and loan.

Overall, the overall financial situation of Xuebong is lower than the industry average, and the current total score is 1.18, ranking low among the 25 companies in the planting and forestry industries. Specifically, the operating capacity and asset quality are excellent.

The scores of the indicators are as follows:

Index type previous period score ranking evaluation of operating ability 4.204.802 excellent cash flow 2.800.8022 weaker profitability 0.800.4024 lower growth ability 2.000.2025 weaker solvency 2.000.2025 lower asset quality 4.004.603 very high total score 2.361.1822 lower than industry average

On the large model of financial diagnosis of flush

Flush (300033) Financial diagnosis model calculates the company's financial scores, highlights and risks based on the company's latest and previous financial data and industry conditions, reflecting the company's disclosed financial position, but not a forecast of the future financial position. The financial score range is 0-5. The higher the score, the better the financial situation and the greater the value of the medium-and long-term investment. In the financial highlights and risk reviews, the five-year average of the indicators related to the "average" keyword, and the latest reporting period data without the "average" keyword. All the above information is based on artificial intelligence algorithm, for reference only, does not represent flush financial point of view, investors operate accordingly, at their own risk.

Learn more about the company's stock diagnostic information >